We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

CERTEST BIOTEC

Certest Biotec, S.L. develops and manufactures IVD products in the human clinical testing field, including rapid test... read more Featured Products: More products

Download Mobile App





CerTest Launches VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit

By LabMedica International staff writers
Posted on 30 Jul 2021
CerTest Biotec (Zaragoza, Spain) has launched VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit, a real-time RT-PCR test designed for the qualitative detection of RNA from genetic mutations in the S gene (P681R, L452R and E484Q) from positive SARS-CoV-2 nasopharyngeal samples. More...


The appearance of genetic mutations is a natural and expected event within the evolution process of a virus. In fact, some specific mutations define the viral genetic groups currently circulating globally. Besides, thanks to the genetic sequencing of the pathogen worldwide, it has been possible to establish patterns of dispersal and evolution of the virus. All viruses, including SARS-CoV-2, mutate over time. Some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures.

At the end of 2020, the appearance of variants with a higher risk prompted the characterization of Variants of Interest (VOI) and Variants of Concern (VOC), in order to facilitate epidemiological control. Some of these SARS-CoV-2 variants are Delta, Kappa and Epsilon. Delta (B.1.617.2 lineage) and Kappa (B.1.617.1 lineage) were closely associated with a huge COVID-19 increase in India during spring 2021. Delta variant has multiple mutations in the Spike protein, including P681R and L452R. Kappa variant has also genetic mutations in the Spike protein, including P681R, L452R and E484Q. Epsilon variant, first detected in California, USA, consists of two distinct lineages B.1.427 and B.1.429 in clade 20C. This variant has multiple mutations in the spike protein, including L452R. An estimated increase in transmission rate of the B.1.427/B.1.429 lineages related to circulating non- B.1.427/B.1.429 lineages was 20%.

All these variants described above show potential reduction in neutralization by some
immunotherapies and reduction of expected effects of vaccines or has been identified to cause community transmission. That is why, their appearance constitute a first-order public health problem that can have an important impact on control of the pandemic. A concern regarding the new variants is that their detection by molecular techniques (RT-PCR) could be affected.

For this reason, VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit has been designed to allow the detection of the main mutation associated with the variant under surveillance. The test is intended for use as an aid to monitor the prevalence of genetic mutations in the S gene (P681R, L452R and E484Q) and to assist in control measures. RNA is extracted from respiratory specimens, complementary DNA (cDNA) is synthesized and amplified using RT-qPCR and detected using fluorescent reporter dye probes specific for genetic mutations in the S gene (P681R, L452R and E484Q).



Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Urine Test Strips
LabStrip U12 mALB/CREA
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.